Reshoring Debate Continues As COVID-19 Drives New Wave Of US Drug Shortages
Executive Summary
As the response to another wave of COVID-19 infections continues, fill rates of critical medicines such as methylprednisolone are dropping. But experts say the answer is not to concentrate manufacturing in US facilities, which could lead to further risks if US supply is disrupted.
You may also be interested in...
USP Exec On Onshoring, Impact Of War-Fueled Metals Turbulence On Pharma
US Pharmacopeia senior director, regional program operations, South Asia, Matruprasad Priyadarshi, discusses with Scrip the need to assess onshoring on a medicine-by-medicine basis and the organization’s efforts to support quality assessments for new mRNA-based therapies. The executive also flags up new trouble spots as metals such as aluminium and nickel, used in medical products and currently witnessing price surges, are mined in the war-torn Russia-Ukraine region.
For Generics, A Victory Lap – And A Warning – On Drug Shortages
Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.
For Generics, A Victory Lap – And A Warning – On Drug Shortages
Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.